UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Cytori Therapeutics, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

23283K204 (CUSIP Number)

January 31, 2018 (Date of Event which Requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☑ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Persons			
	PostFina			
2	2 Check the Appropriate Box if a Member of a Group			
	(a) 🗆	(1	b) \square	
3	3 SEC Use Only			
4	Citizen or Place of Organization			
	Switzerland			
		5	Sole Voting Power	
Number of			5,540,054	
Shares 6 S		6	Shared Voting Power	
	Beneficially Owned by 0			
Each		7		
Reporting Person				
	With		5,540,054	
	With	8	Shared Dispositive Power	
			0	
9 Aggregate Amount Beneficially Owned by Each Reporting Person				
	5,540,05	4		
10	10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares			
	Not Applicable			
11	Percent of a Class Represented by Amount in Row 9			
	12.0%			
12	12 Type of Reporting Person			
	FI			

ITEM 1. (a) Name of Issuer:

Cytori Therapeutics, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices:

3020 Callan Road San Diego, CA 92121

ITEM 2. (a) Name of Person Filing:

PostFinance AG

(b) Address or Principal Business Office:

Mingerstrasse 20 3030 Bern Switzerland

(c) Citizenship of each Reporting Person is:

Switzerland

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

23283K204

ITEM 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

- a) Droker or dealer registered under section 15 of the Act (15 U.S.C. 780);
- (b) \square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) \square Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)

 Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) \square An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) \Box An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

ITEM 7.

ITEM 8.

Not applicable.

Not applicable.

Identification and Classification of Members of the Group

ITEM 9. Notice of Dissolution of Group

Not applicable.

ITEM 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to banks regulated under the laws of Switzerland is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

CUSIP No. 23283K204 Schedule 13G Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 1, 2018

PostFinance AG

By: /s/ Philip Thalmann
Name: Philip Thalmann
Title: Legal Officer

By: /s/ Emanuel Kunz
Name: Emanuel Kunz
Title: Legal Officer